Avalo regains Nasdaq minimum bid compliance; subject to 1-year panel monitor

Avalo Therapeutics, Inc.

Received Nasdaq letter January 30, 2024 confirming compliance with $1.00 bid price rule.
Reverse stock split on December 28, 2023 brought stock above $1.00 since December 29, 2023.
Mandatory panel monitor for one year from January 30, 2024; no cure period if noncompliant again.
If noncompliant during monitor, Nasdaq will issue delist letter; company can request hearing.
Failure to satisfy panel could result in delisting from Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.